Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow Blasts
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to learn how patients with myelodysplastic syndrome (MDS)
respond to the study drug dasatinib. The study drug, dasatinib, has been approved by the U.S.
Food and Drug Administration (FDA) for treatment of leukemia, but has not been approved for
the treatment of other kinds of cancer. The use of dasatinib in this study is considered
experimental.
Phase:
N/A
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute